Axsome Therapeutics removed from Russell 2000 as it shifts to Russell Midcap Growth index

Axsome Therapeutics, Inc. (NASDAQ: AXSM) was taken out of the Russell 2000 Index and the Russell 2000 Growth Benchmark on June 28, 2026, and simultaneously added to the Russell Midcap Growth Benchmark. The re‑classification reflects the company’s rising market capitalization and signals a shift in the pool of passive funds that may hold its shares.

Core developments

According to two MarketScreener notices, Axsome’s removal from the Russell 2000 and its growth sub‑index was confirmed on June 28, 2026. The same day the firm was listed as a new constituent of the Russell Midcap Growth Benchmark, a basket that tracks larger‑cap growth stocks outside the small‑cap universe. The dual announcements indicate that the index provider has re‑evaluated Axsome’s size relative to the thresholds that define the two indexes.

"Axsome Therapeutics, Inc. (NasdaqGM: AXSM) dropped from Russell 2000 Index"MarketScreener, June 28, 2026

"Axsome Therapeutics, Inc. (NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark"MarketScreener, June 28, 2026

"Axsome Therapeutics, Inc. (NasdaqGM: AXSM) added to Russell Midcap Growth Benchmark"MarketScreener, June 28, 2026

The Russell 2000 comprises roughly 2,000 of the smallest companies in the broader Russell 3000, and its growth sub‑index isolates those with higher price‑to‑earnings ratios and earnings growth expectations. By moving into the Midcap Growth basket, Axsome now aligns with firms whose market values sit between the small‑cap and large‑cap tiers, typically ranging from $2 billion to $10 billion. While the exact market cap of Axsome was not disclosed in the notices, the index shift alone implies it has crossed the size boundary used by FTSE Russell.

Why it matters

Index inclusion matters because a sizable share of institutional capital is managed on a passive basis. Funds that track the Russell 2000 must automatically sell Axsome’s shares, while those that follow the Russell Midcap Growth Benchmark will add them. The net effect can be a short‑term liquidity shock, especially for a biotech whose trading volume is already modest.

Beyond the mechanical buying and selling, the move alters the perception of Axsome’s growth profile. The Russell Midcap Growth index is often viewed as a more stable growth arena, populated by companies that have demonstrated sustained revenue expansion and lower volatility than many pure small‑caps. Analysts may therefore recalibrate their expectations for Axsome’s risk‑adjusted returns, potentially influencing coverage upgrades or downgrades.

MarketBeat’s explanation of how investors use the Russell 2000 underscores the index’s role as a barometer for the U.S. small‑cap segment. When a stock exits the index, it can lose exposure to a broad set of ETFs, mutual funds, and institutional mandates that rely on the index as a benchmark. Conversely, entering the Midcap Growth list opens the company to a different cohort of funds that prioritize growth‑oriented mid‑cap exposure.

"Russell 2000 Index, How Investors Use it For Profitable Trading"MarketBeat, 2026

Differing viewpoints and reactions

While the index announcements are factual, market participants have offered varied interpretations. Some analysts view the shift as a sign that Axsome’s valuation has matured, suggesting that the company is moving out of the high‑risk, high‑reward small‑cap category. Others caution that the transition could temporarily depress the stock price as index‑tracking funds unload shares, a phenomenon observed in past re‑balancing cycles.

TradingView’s live chart for AXSM shows the stock trading near a key resistance level, with recent volume spikes coinciding with the index news. Traders on the platform have posted mixed sentiment, with some posting bullish notes based on the company’s pipeline of neuro‑psychiatric drugs, while others flag the risk of short‑term price pressure from the index turnover.

"AXSM Stock Price and Chart — NASDAQ:AXSM"TradingView, June 30, 2026

Overall, the consensus among sector specialists is that the index move is a neutral‑to‑slightly‑positive development for Axsome’s long‑term investors, provided the company continues to meet its clinical milestones. Short‑term traders, however, are likely to watch the price action closely for any volatility spurred by fund rebalancing.

What’s next

In the coming weeks, Axsome will need to manage the liquidity impact of the index change while keeping its drug development timelines on track. The firm’s next earnings release, slated for early Q4 2026, will offer a chance to gauge whether the index shift has translated into any material change in shareholder composition or stock performance.

Investors should also monitor any further index reviews by FTSE Russell, which conducts annual re‑constitution in June. If Axsome’s market cap continues to rise, it could eventually qualify for the Russell 1000 or even the S&P 500, dramatically expanding its passive‑investment base.

Meanwhile, analysts covering the biotech sector will likely adjust their valuation models to reflect the new benchmark exposure, and fund managers may re‑evaluate their allocation to AXSM within growth‑focused mid‑cap strategies.